October 27, 2016 / 10:47 AM / a year ago

BRIEF-Alexion initiates simultaneous registration trials of ALXN1210 for patients with PNH and AHUS

Oct 27 (Reuters) - Alexion Pharmaceuticals Inc

* Alexion initiates simultaneous registration trials of ALXN1210 for patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (ahus)

* Trials to evaluate alxn1210 administered every eight weeks in patients with PNH and AHUS; enrollment to begin in q4

* Plans to initiate a Phase 3 trial of ALXN1210 in pediatric patients with ahus in 2017

* Commenced dosing of a new formulation of alxn1210 administered subcutaneously in healthy volunteers in a phase i study Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below